Amino-Modified Polylactic Acid Nanofibre Microspheres as Drug Sustained Release Carriers for Alendronate

References

• Whitaker, M.; Guo, J.; Kihoe, T.; Benson, G. Bisphosphonates for Osteoporosis—Where Do We go from here? N. Engl. J. Med. 2012, 366, 2048–2051.
   PubMed Web of Science ®Google Scholar
• Black, D. M.; Bauer, D. C.; Schwartz, A. V.; Cummings, S. R.; Rosen, C. J. Continuing Bisphosphonate Treatment for Osteoporosis for Whom and for how Long? N. Engl. J. Med. 2012, 366, 2051–2053.
   PubMed Web of Science ®Google Scholar
• Silverman, S. L.; Maricic, M.. Recent Developments in Bisphosphonate Therapy. Semin. Arthritis Rheum. 2007, 37, 1–12.
   PubMed Web of Science ®Google Scholar
• Drake, M. T.; Clarke, B. L.; Khosla, S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clin. Proc. 2008, 83, 1032–1045.
   PubMed Web of Science ®Google Scholar
• Low, S. A.; Kopecek, J. Targeting Polymer Therapeutics to Bone. Adv. Drug Deliv. Rev. 2012, 64, 1189–1204.
   PubMed Web of Science ®Google Scholar
• Bone, H. G.; Hosking, D.; Devogelaer, J. P.; Tucci, J. R.; Emkey, R. D.; Tonino, R. P.; Rodriguez-Portales, J. A.; Downs, R. W.; Gupta, J.; Santora, A. C.; et al. Ten Years’ Experience with Alendronate for Osteoporosis in Postmenopausal Women. N. Engl. J. Med. 2004, 350, 1189–1199.
   PubMed Web of Science ®Google Scholar
• Schnitzer, T.; Bone, H. G.; Crepaldi, G.; Adami, S.; McClung, M.; Kiel, D.; Felsenberg, D.; Recker, R. R.; Tonino, R. P.; Roux, C.; et al. Therapeutic Equivalence of Alendronate 70 mg Once-Weekly and Alendronate 10 mg Daily in the Treatment of Osteoporosis. Aging Clin. Exp. Res. 2000, 12, 1–12.
   Web of Science ®Google Scholar
• Yong, Z.; Elizebeth, J.; Rand, D.; Lenard M. L. Effect of Indomethacin on Bile Acid-Phospholipid Interactions: Implication for Small Intestinal Injury Induced by Nonsteroidal Anti-Inflammatory Drugs. Am. J. Physiol. Gastrointest Liver Physiol. 2010, 298, 722–731.
   Web of Science ®Google Scholar
• Cremers, S.; Papapoulos, S. Pharmacology of Bisphosphonates. Bone 2011, 49, 42–49.
   PubMed Web of Science ®Google Scholar
• Ezra, A.; Golomb, G. Administration Routes and Delivery Systems of Bisphosphonates for the Treatment of Bone Resorption. Adv. Drug Deliv. Rev. 2000, 42, 175–195.
   PubMed Web of Science ®Google Scholar
• Ezra, A.; Hoffman, A.; Breuer, E.; Alferiev, I. S.; Mönkkönen, J.; El Hanany-Rozen, N.; Weiss, G.; Stepensky, D.; Gati, I.; Cohen, H.; et al.; A Peptide Prodrug Approach for Improving Bisphosphonate Oral Absorption. J. Med. Chem. 2000, 43, 3641–3652.
   PubMed Web of Science ®Google Scholar
• Wright, J. E.; Gittens, S. A.; Bansal, G.; Kitov, P. I., Sindrey, D.; Kucharski, C.; Uludağ, H. A Comparison of Mineral Affinity of Bisphosphonate-Protein Conjugates Constructed with Disulfide and Thioether Linkages. Biomaterials 2006, 27, 769–784.
   PubMed Web of Science ®Google Scholar
• Pazianas, M.; Abrahamsen, B. Safety of Bisphosphonates. Bone 2011, 49, 103–110.
   PubMed Web of Science ®Google Scholar
• Gaba, B.; Fazil, M.; Ali, A.; Baboota, S.; Sahni, J. K.; Ali, J. Nanostructured Lipid (NLCs) Carriers as a Bioavailability Enhancement Tool for Oral Administration. Drug Delivery 2015, 22, 691–700.
   PubMed Web of Science ®Google Scholar
• Liu, Y. F.; Liu, R.; Li, X. Y.; Song, Z.; Zhao, X. H. Development of Docetaxel and Alendronate-Loaded Chitosan-Conjugated Polylactide-Co-Glycolide Nanoparticles: In vitro Characterization in Osteosarcoma Cells. Trop. J. Pharm. Res. 2016, 15, 1353–1360.
   Web of Science ®Google Scholar
• Yang, H.; Gao, H. C.; Wang, Y. J. Hollow Hydroxyapatite Microsphere: A Promising Carrier for Bone Tissue Engineering. J. Microencapsulation 2016, 33, 421–426.
   PubMed Web of Science ®Google Scholar
• Hosny, K. M. Alendronate Sodium as Enteric Coated Solid Lipid Nanoparticles; Preparation, Optimization, and In Vivo Evaluation to Enhance its Oral Bioavailability. Plos One 2016, 11, 1–14
   Web of Science ®Google Scholar
• Baea, J.; Parkb, J. W. Preparation of an Injectable Depot System for Long-Term Delivery of Alendronate and Evaluation of its Anti-Osteoporotic Effect in an Variectomized Rat Model. Int. J. Pharm. 2015, 480, 37–47.
   PubMed Web of Science ®Google Scholar
• Deca, A. G.; Belu, I.; Croitoru, O. Formulation and In Vitro Evaluation of Alendronate Sodium/PLGA Microspheres for Applications in Bone Related Disorders. Curr. Health Sci. J. 2015, 41, 246–250.
   Google Scholar
• Zafar, N.; Bitar, A.; Valour, J. P.; Fessi, H.; Elaissari, A. Elaboration of Ammonio Methacrylate Copolymer Based Spongy Cationic Particles via Double Emulsion Solvent Evaporation Process. Mater. Sci. Eng. C 2016, 61, 85–96.
   PubMed Web of Science ®Google Scholar
• Fan, Q.; Qi, F.; Miao, C. Y.; Yue, H.; Gong, F.; Wu, J.; Ma, G.; Su, Z. Direct and Controllable Preparation of Uniform PLGA Particles with Various Shapes and Surface Morphologies. Colloids Surf. A: Physicochem. Eng. Aspects 2016, 500, 177–185.
   Web of Science ®Google Scholar
• Floyd, J. A.; Galperin, A.; Ratner, B. D. Drug Encapsulated Aerosolized Microspheres as a Biodegradable, Intelligent Glioma Therapy. J. Biomed. Mater. Res. Part A 2016, 104, 544–552.
   PubMed Web of Science ®Google Scholar
• Wanga, Y. J.; Molinb, D. G. M.; Sevrinc, C.; Grandfils, C.; van den Akker, N. M.; Gagliardi, M.; Knetsch, M. L.; Delhaas, T.; Koole, L. H. In Vitro and In Vivo Evaluation of Drug-Eluting Microspheres Designed for Transarterial Chemoembolization Therapy. Int. J. Pharm. 2016, 503, 150–162.
   PubMed Web of Science ®Google Scholar
• Lassalle, V.; Luján, M. PLA Nano- and Microparticles for Drug Delivery: An Overview of the Methods of Preparation. Macromol. Biosci. 2007, 6, 767–783.
   Web of Science ®Google Scholar
• Piñón-Segundo, E.; Nava-Arzaluz, M.; Lechuga-Ballesteros, D. Pharmaceutical Polymeric Nanoparticles Prepared by the Double Emulsion- Solvent Evaporation Technique. Recent Pat. Drug Deliv. Formul. 2012, 6, 224–235.
   PubMedGoogle Scholar
• Bouza, R.; Castro, M. M.; Dopico-García, S.; González-Rodríguez, M. V.; Barral, L. F.; Bittmann, B. Polylactic Acid and Poly (3-hydroxybutyrate-co-3-hydroxyvalerate) Nano and Microparticles for Packaging Bioplastic Composites. Polym. Bull. 2016, 73, 3485–3502.
   Web of Science ®Google Scholar
• Jadranka, K.; Ivana, J.; Jovan, N.; Prstojević, D.; Marinković, V. Spectrophotometric Determination of Alendronate in Pharmaceutical Formulations via Complex Formation with Fe (Ⅲ) Ions. J. Pharm. Biomed. Anal. 2002, 28, 1215–1220.
   PubMed Web of Science ®Google Scholar
• Srinivasan, S.; Jayasree, R.; Chennazhi, K. P.; Nair, S. V.; Jayakumar, R. Biocompatible Alginate/Nano Bioactive Glass Ceramic Composite Scaffolds for Periodontal Tissue Regeneration. Carbohydr. Polym. 2012, 87, 274–283.
   PubMed Web of Science ®Google Scholar
• Samuelov, Y.; Donbrow, M.; Friedman, M. Sustained Release of Drugs from Films and Kinetics of Drug Release. J. Pharm. Sci. 1979, 68, 325–329.
   PubMed Web of Science ®Google Scholar
• Dredán, J.; Antal, I.; Rácz, I. Evaluation of Mathematical Models Describing Drug Release from Lipophilic Matrices. Int. J. Pharm. 1996, 145 61–64.
   Web of Science ®Google Scholar
• Higuchi, T. J. Mechanism of Sustained Action Medication: Theoretical Analysis of Rate of Release of Solid Drugs Dispersed in Solid Matrices. J. Pharm. Sci. 1963, 52, 1145–1149.
   PubMed Web of Science ®Google Scholar
• Ritger, P. L.; Peppas, N. A. A Simple Equation for Description of Solute Release I. Fickian and Non-Fickian Release from Non-Swellable Devices in the Form of Slabs, Spheres, Cylinders or Discs. J. Control Release 1987, 5, 23–36.
   Google Scholar
• Langer, R. S.; Peppas, N. A. Present and Future Applications of Biomaterials in Controlled Drug Delivery Systems. Biomaterials 1981, 2, 201–214.
   PubMed Web of Science ®Google Scholar